COVID Vaccine Side Effects: Common, Rare & Long-Term Risks

If you’ve rolled up your sleeve for a COVID shot and spent the next two days feeling sorry for yourself, you’re in very good company. Billions of doses later, mild discomfort remains the overwhelming norm, while genuinely rare risks keep regulators busy poring over pharmacovigilance data from Ireland, the US, and beyond. This guide maps what the science actually shows — from injection-site soreness to the myocarditis signal that surfaced in young males after mRNA vaccines.

Most side effects: mild to moderate · Common reactions resolve: within days · Rare side effects identified: transverse myelitis, acute disseminated encephalomyelitis · Monitoring bodies: HPRA, HSE, RIVM

The following table summarizes key monitoring data and safety findings from Irish and international regulatory sources.

What are the most common side effects?

The bulk of COVID vaccine side effects look and feel like what you’d expect from any jab — a sore arm, a bit of fatigue, maybe a low-grade fever. Ireland’s Health Products Regulatory Authority (HPRA) received 21,471 reports of suspected side effects through January 31, 2026, with the overwhelming majority classified as mild to moderate (HPRA Official Safety Page). By the end of 2021, 17,871 of those reports had landed in HPRA’s database — a reflection of peak vaccination activity that year (HPRA Official Safety Page). Early in the campaign, when 147,700 first doses and just 13,800 second doses had been administered in Ireland, HPRA logged 740 reports in a single update, all described as mostly mild and consistent with the product information (HPRA Second Safety Update via PMC).

Local reactions

• Pain, redness, or swelling at the injection site — the most frequently reported local reaction across all vaccine types
• Dizziness and fainting episodes, particularly immediately after vaccination, not specific to any brand
• Hives and itchiness reported in a subset of recipients, some requiring medical attention

Systemic symptoms

• Fever and chills accompanying fatigue, headache, and muscle aches
• Nausea reported across Pfizer, Moderna, and AstraZeneca recipients
• Menstrual disturbances noted in a peer-reviewed study tracking long-term adverse events (PMC Study on LTAEs)

Duration of common effects

Most systemic symptoms peak within 24–48 hours of vaccination and resolve within three to five days. A study of 500 participants found that 16% reported long-term adverse events — primarily fatigue (32 cases), menstrual disturbances (15), myalgia (8), arthralgia (6), dizziness (4), and headache (4) — though the researchers noted no significant association with age, gender, or medical history (PMC Study on LTAEs). The implication: most people who experience symptoms beyond a week are not in any identifiable risk group.

How long do COVID shot side effects last?

For the vast majority of recipients, the answer is straightforward: a few days. The CDC’s guidance and HPRA’s product-aligned reporting both confirm that common side effects peak in the first 48 hours and subside within a week for almost everyone (HPRA Official Safety Page). The HSE recommends that anyone experiencing symptoms beyond ten days consult a healthcare professional, though this is framed as a precaution rather than an expected outcome.

Short-term resolution

Pfizer’s clinical data and real-world pharmacovigilance from Australia’s AusVaxSafety program show a consistent profile: injection-site pain resolves within 1–3 days, systemic symptoms like fatigue and headache within 3–5 days (AusVaxSafety). Fever, when it occurs, typically appears within 24 hours and resolves within 48 hours without intervention. What to watch for: symptoms that start suddenly after day 7, or that worsen rather than improve, warrant medical evaluation.

Factors influencing duration

Individual variation is real but not predictable by demographic factors. The PMC study found no significant association between long-term adverse events and age, gender, or prior medical history (P > 0.05) (PMC Study on LTAEs). The pattern suggests that if you had a strong immediate reaction, you may be more likely to report lingering symptoms — but this is not a causal finding. The HPRA data shows a steep decline in reports over time: 399 in 2023, 212 in 2024, and 127 in 2025, reflecting both reduced vaccination rates and a regression to baseline symptom reporting as campaigns wind down (HPRA Official Safety Page).

What are the long term side effects of the COVID vaccine?

This is where the conversation gets more nuanced — and where reputable sources become essential. The scientific consensus, backed by tier-1 regulatory bodies like HPRA, CDC, and EMA, is that no COVID vaccine has demonstrated a pattern of long-term adverse events beyond the acute and subacute windows already identified (HPRA Official Safety Page). A UAB infectious disease expert, Dr. Paul Goepfert, put it plainly: “You wouldn’t expect any of these vaccines to have any long-term side effects. And in fact, this has never occurred with any vaccine” (UAB Reporter).

Reported long-term adverse events

The peer-reviewed literature documents a handful of signals worth knowing about. Myocarditis — inflammation of the heart muscle — has been confirmed as a rare causal consequence of mRNA vaccines (Pfizer and Moderna) by the CDC, occurring in approximately 1 in a million recipients, typically within one month of vaccination (UAB Reporter). The condition has been listed in Pfizer’s USPI Warnings and Precautions since the risk was identified (Pfizer Myocarditis Analyses). An FDA-funded study tracking 333 myocarditis cases at a median follow-up of 178 days found no cardiac-related deaths and no patients requiring heart transplantation (Pfizer Myocarditis Analyses). An 18-month Australian study of 256 cases showed low hospitalization rates, no deaths, and improving quality of life outcomes (Pfizer Myocarditis Analyses).

Ongoing monitoring

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which includes HPRA participation, assessed worldwide safety data through 2022 and continues routine monitoring (HPRA Official Safety Page). Rare neurological conditions — transverse myelitis and acute disseminated encephalomyelitis (ADEM) — were identified as new signals requiring updates to product information, per BMJ reporting. The HPRA Oct 2021 update documented 15,424 reports with 90 deaths reviewed, with most deaths occurring in individuals over 75 with underlying natural causes — not attributed to the vaccine (AFP Fact Check).

Does the COVID vaccine cause chronic health problems?

The honest answer from available evidence is: not in any pattern that has been reliably distinguished from background rates of illness. The CDC confirms a causal link between mRNA vaccines and rare myocarditis, but the vast majority of cases resolve by hospital discharge (CDC Myocarditis Page). FDA data notes MRI improvement in most teen and young adult cases, though long-term effects continue to be studied (Vaccine Advisor). Higher myocarditis risk has been observed in young males within 14 days after a second mRNA dose — a signal Pfizer has acknowledged and included in its warnings (Pfizer Myocarditis Analyses).

Chronic fatigue reports

Fatigue is the most frequently reported long-term symptom in the peer-reviewed literature, but its causality is unclear. The 500-participant PMC study found fatigue significantly associated with Sinopharm recipients (P=0.04) but not with Pfizer (PMC Study on LTAEs). That distinction matters: if fatigue were purely a vaccine adjuvant effect, we’d expect similar rates across platforms. The catch: without long-term controlled studies, we cannot rule out reporting bias or post-acute infection symptoms being misattributed to vaccination.

Autoimmune and hematologic signals

Rare single reports of thrombosis, bleeding tendency, and left arm paresthesia have been documented in Pfizer and Sinopharm recipients (PMC Study on LTAEs). These are not established causal relationships — they fall into the “signals requiring further monitoring” category rather than confirmed adverse event profiles. The CDC notes that Novavax also shows increased myocarditis risk per non-US data, suggesting the risk is not unique to mRNA platforms but is most clearly documented for Pfizer and Moderna (CDC Myocarditis Page).

What are the worst effects of the Pfizer vaccine?

Pfizer’s Comirnaty vaccine — the dominant COVID vaccine in Ireland’s rollout — has a safety profile that compares favorably to other available platforms. The PMC long-term adverse event study of 500 participants found the Pfizer-BioNTech vaccine “least associated with LTAEs” compared to Sinopharm and AstraZeneca (PMC Study on LTAEs). AusVaxSafety’s post-marketing surveillance confirmed that Pfizer’s safety profile matches clinical trial data and global real-world experience (AusVaxSafety).

Severe reactions

Anaphylaxis and Bell’s palsy were flagged for monitoring by HPRA in its January 2021 safety update — early in the campaign, with 740 reports logged at that point (HPRA Second Safety Update via PMC). Both remain rare. The HSE affirms that vaccines met safety standards despite rapid development, a point corroborated by Ireland’s MDEAS oversight body (MDEAS HSE Info). Deaths reported post-vaccination have been reviewed and attributed to natural causes or underlying disease in the vast majority of cases — HPRA’s October 2021 review of 90 death reports found no causal link established (AFP Fact Check).

Pfizer-specific data

The most clinically significant Pfizer-specific risk is myocarditis. CDC confirms causality for mRNA vaccines broadly, and Pfizer’s own analyses — incorporating US, French, Nordic, UK studies and a meta-analysis — characterize the risk as very rare (Pfizer Myocarditis Analyses). Heart issues post-mRNA vaccination are rare and typically occur within the first week, per CDC (Pfizer Facts Page). The pattern of higher risk in young males after the second dose led to updated warnings and guidance for this demographic.

What are COVID vaccine side effects on the brain?

Neurological symptoms after COVID vaccination are documented but generally mild and transient. Dizziness and headache are among the most common systemic reports across all platforms (HSE Side Effects Page). More serious neurological signals — transverse myelitis and ADEM — have been identified as rare adverse events requiring product information updates, as reported by BMJ (HPRA Official Safety Page). These conditions involve inflammation of the spinal cord or brain and typically present with motor weakness, sensory changes, or cognitive symptoms.

The context matters: transverse myelitis and ADEM are extraordinarily rare in the general population (estimated incidence of 1–4 per 100,000 annually), so reports post-vaccination are being monitored as signals rather than confirmed causal relationships. The EMA PRAC continues to assess these cases as part of its ongoing safety evaluation (HPRA Official Safety Page).

“You wouldn’t expect any of these vaccines to have any long-term side effects. And in fact, this has never occurred with any vaccine.”

— Dr. Paul Goepfert, Director of the Alabama Vaccine Research Clinic, UAB

“Mid-term clinical outcomes of 333 individuals with COVID-19 vaccine-associated myocarditis at a median follow-up of 178 days were reassuring, with no reported cardiac related deaths or need for heart transplantations.”

— FDA-Funded Research Team (via Pfizer Myocarditis Analyses)

“Reports describing a death are carefully reviewed. However, it can be expected that fatalities due to progression of underlying disease or natural causes will continue to occur, including following vaccination. This does not mean that the vaccine caused the deaths.”

— HPRA, Irish Medicines Regulatory Authority

The picture that emerges from Ireland’s pharmacovigilance database and global research is one of overwhelming safety for the overwhelming majority. HPRA’s 21,471 reports — spread across millions of doses administered since 2021 — represent voluntary submissions from a population that had strong incentives to report anything unusual. The steep drop in reports as vaccination campaigns wound down (from 17,871 in 2021 to 127 in 2025) reflects both reduced dosing and the natural regression of hypervigilant reporting. Rare risks exist — myocarditis, transverse myelitis, ADEM — but they are rare, tracked, and mostly resolvable. For people weighing a booster or considering primary vaccination, the regulatory and clinical evidence argues that the balance of known risks and proven benefits sits firmly on the side of vaccination for most populations.

Related reading: What Causes Vertigo? Top Triggers, Red Flags & Insights · Doctors at Pacific Fair – GPs List, Hours and Services

HPRA data on Pfizer effects aligns closely with international perspectives like risks, duration and guidance, where most reactions prove mild and short-lived.

Frequently asked questions